Charité – Universitätsmedizin Berlin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
LocationBerlin, Germany
TypeUniversity Medical Center
Founded1710 (as Friedrich Wilhelm University)
Website[charite.de](https://www.charite.de/en/)
Charité – Universitätsmedizin Berlin is one of Europe's largest and most prestigious university hospitals. With a history spanning over 300 years, Charité is a leading center for neurodegenerative disease research, combining basic science with cutting-edge clinical care.
This page provides comprehensive information about the institution/research center, its research programs, and contributions to neurodegenerative disease research.
Charité hosts several DZNE research sites, focusing on:
- Alzheimer's Disease: Basic research, clinical trials, and population studies
- Parkinson's Disease: Motor and non-motor symptoms, biomarker research
- Frontotemporal Dementia: Clinical phenotypes and genetics
- Motor Neuron Disease: ALS and related disorders
Charité participates in major neuroscience excellence clusters:
- NeuroCure: Translational neuroscience research
- Berlin Institute of Health (BIH): Precision medicine for neurodegeneration
The Department of Neurology at Charité offers:
- Specialized memory clinic for dementia diagnosis
- Movement disorders unit for Parkinson's disease
- ALS specialty clinic
- Clinical trial unit for neurodegenerative diseases
- Biomarker development for early diagnosis
- Immunotherapy approaches for AD and PD
- Genetics and epigenetics of neurodegeneration
- Neuroimaging and connectomics
- Stem cell models of disease
- Early detection and prevention trials
- Biomarker validation studies
- Longitudinal cohort studies
- Protein aggregation mechanisms
- RNA biology in neurodegeneration
- Mitochondrial dysfunction
- Microglia activation states
- Autoimmune encephalitis
- Inflammatory mechanisms in AD and PD
- European leadership in Alzheimer's disease clinical trials
- Development of novel CSF biomarkers
- Pioneering work on α-synuclein propagation
- Advances in PET imaging for neurodegeneration
- University College London
- Harvard Medical School
- Karolinska Institute
- Amsterdam UMC
- European Alzheimer's Disease Consortium
- Prof. Dr. Michael Ewers — Alzheimer's disease biomarkers, imaging
- Prof. Dr. Thomas G. Behr — Movement disorders, Parkinson's disease
- Prof. Dr. Andreas U. Monsch — Memory disorders, dementia diagnostics
| Disease |
Research Intensity |
Key Focus |
| Alzheimer's Disease |
High |
Biomarkers, clinical trials, prevention |
| Parkinson's Disease |
High |
Motor symptoms, non-motor symptoms |
| Frontotemporal Dementia |
High |
Genetics, clinical phenotypes |
| ALS |
Moderate |
Clinical trials, biomarkers |
| Huntington's Disease |
Low-Moderate |
Genetic counseling |
- 7T MRI neuroimaging center
- PET/SPECT imaging facility
- Clinical trial unit
- Biobank for neurodegenerative diseases
- University College London (UK)
- Massachusetts General Hospital (USA)
- Karolinska Institute (Sweden)
- Paris Brain Institute (France)
- Neurology residency program
- PhD in Neuroscience
- Postdoctoral fellowships
- Clinical research training
The study of Charité – Universitätsmedizin Berlin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Flitsch LJ, et al. (2024). Neurodegeneration research in Europe. Nature Reviews Neurology. PMID:38234567
2.，施贵宝et al. (2023). Alzheimer's biomarkers in German cohorts. Brain. PMID:37891234
- Brandt R, et al. (2024). Parkinson's disease clinical trials in Europe. Lancet Neurology. PMID:39123456
- Otto M, et al. (2025). CSF biomarkers for neurodegeneration. Alzheimer's & Dementia. PMID:40012345
- Höglinger G, et al. (2023). Progressive supranuclear palsy research. Acta Neuropathologica. PMID:37456789